Alphonse Hubsch

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Experiences of Immunoglobulin Therapy for Those with a Confirmed Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Mixed-Methods Study with a Qualitative Patient Perspective Focus.

Experiences of Immunoglobulin Therapy for Those with a Confirmed Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Mixed-Methods Study with a Qualitative Patient Perspective Focus.

Journal: Patient preference and adherence

Published: July 24, 2025

An Evaluation of the Real-World Effectiveness of Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy.

An Evaluation of the Real-World Effectiveness of Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy.

Journal: Neurology and therapy

Published: April 15, 2025

Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.

Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.

Journal: Transfusion

Published: October 20, 2021

Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.

Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.

Journal: Transfusion

Published: February 24, 2020

Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.

Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.

Journal: Transfusion

Published: December 10, 2019

Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.

Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.

Journal: Analytical biochemistry

Published: August 19, 2019

Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.

Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.

Journal: Transfusion

Published: March 29, 2018

Correlation of Radiation Dose Estimates by DIC with the METREPOL Hematological Classes of Disease Severity.

Correlation of Radiation Dose Estimates by DIC with the METREPOL Hematological Classes of Disease Severity.

Journal: Radiation research

Published: March 02, 2018

Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital-based cohort study in the US.

Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital-based cohort study in the US.

Journal: American journal of hematology

Published: September 28, 2017

Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.

Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.

Journal: Transfusion

Published: November 29, 2016

Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.

Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 21, 2016

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.

Journal: Journal of clinical immunology

Published: July 06, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026